Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits
- 1 January 1992
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (1) , 56-58
- https://doi.org/10.1128/aac.36.1.56
Abstract
Cilofungin has potent in vitro activity against Candida albicans, but previous in vivo models using twice daily intermittent dosing regimens have not consistently demonstrated in vivo efficacy. Because of the pharmacokinetics of cilofungin in rabbits, it has been suggested that administration by continuous intravenous infusion might be more effective. We compared the in vivo efficacy of continuous intravenous infusion of cilofungin with that of amphotericin B in a rabbit model of disseminated candidiasis. Cilofungin prepared as previously described in phosphate-buffered 33% polyethylene glycol was lethal to infected rabbits in this model, as was phosphate-buffered 33% polyethylene glycol alone. In contrast, cilofungin in 26% polyethylene glycol and sterile water administered by continuous intravenous infusion was tolerated by rabbits, was significantly more effective than amphotericin therapy in reducing candida colony counts in kidney tissue, and was as effective as amphotericin therapy in lung and spleen tissue and in cardiac valvular vegetations. The dosage regimen and diluent used in some previous studies may have adversely affected outcome of treatment with cilofungin.Keywords
This publication has 12 references indexed in Scilit:
- Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasisAntimicrobial Agents and Chemotherapy, 1991
- Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbitsAntimicrobial Agents and Chemotherapy, 1990
- In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) againstAspergillus andCandida speciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Comparison of cilofungin and amphotericin B for therapy of murine candidiasisAntimicrobial Agents and Chemotherapy, 1990
- Comparative effects of cilofungin and amphotericin B on experimental murine candidiasisAntimicrobial Agents and Chemotherapy, 1990
- Treatment of experimental disseminated candidiasis with cilofunginAntimicrobial Agents and Chemotherapy, 1989
- Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimensAntimicrobial Agents and Chemotherapy, 1989
- Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activityAntimicrobial Agents and Chemotherapy, 1988
- In vitro and in vivo anti-Candida activity and toxicology of LY121019.The Journal of Antibiotics, 1984
- Experimental endocarditis. IV. Tricuspid and aortic valve infection with Candida albicans in rabbits.1972